Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Radical Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07603349Phase 3Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2026
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Median Event-Free Survival at 13 months and 2-year Event-Free Survival Rate. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07603349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603349.